In This Section

Program

Please note that this meeting will take place as an in-person event in San Diego and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

Thursday, January 28

Friday, January 29

Saturday, January 30

SUNday, January 31

Thursday, January 28

Opening Keynote Lecture I

5:30-6:15 p.m.

Rising Star Keynote Lecture

6:15 – 6:45 p.m.

  • Neeha Zaidi, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland

Poster Session A and Welcome Reception

7-9 p.m.

Friday, January 29

Plenary Session 1: RAS Signaling: RAS Isoforms, Effectors, and Activity Regulators

8-10 a.m.

  • Frank McCormick, University of California, San Francisco, San Francisco, California
  • Targeting RAS signaling for future therapy of NRAS-driven melanoma
    Martin McMahon, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah
  • How SHP2 activates RAS
    Benjamin Neel, NYU Langone Health, New York, New York

Break

10-10:20 a.m.

Plenary Session 2: Preclinical and Clinical Advances in PDAC

10:20 a.m. –12:20 p.m.

  • Channing Der, Lineberger Comprehensive Cancer Center, University of  North Carolina at Chapel Hill, Chapel Hill, North Carolina
  • Ignacio Garrido-Laguna, Moffitt Cancer Center, Tampa, Florida
  • Understanding Ras: It ain’t over ’til it’s over
    Dafna Bar-Sagi, Grossman School of Medicine, New York University, New York, New York

Lunch Break

12:20- 2 p.m.

Plenary Session 3: Preclinical and Clinical Advances in Lung Cancer

2-4 p.m.

  • KRAS mutant NSCLC: At the end of the beginning
    Melissa Johnson, Sarah Cannon Research Institute, Nashville, Tennessee
  • Chiara Ambrogio, Candiolo Cancer Institute, Candiolo, Italy

Break

4-4:20 p.m.

Plenary Session 4: Preclinical and Clinical Advances in Colorectal Cancer

4:20-6:20 p.m.

  • Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts
  • The landscape of RAS in CRC
    David Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas

Poster Session B

6:30-8:30 p.m.

Saturday, January 30

Clinical Trials from Abstracts

8-10 a.m.

Break

10-10:20 a.m.

Plenary Session 5: Novel Therapeutic Approaches to Targeting the RAS Pathway

10:20-11:40 a.m.

  • Targeting RAS with Antibody-Drug Conjugates
    Raffaele Colombo, Zymeworks Inc., Vancouver, British Columbia, Canada

Lunch

11:40 a.m- 1:20 p.m.

Plenary Session 6: RAS, Immunotherapy, Prevention, and Interception

1:20 – 3:20 p.m.

  • Targeting the interplay between oncogenic RAS signaling and tumor immune evasion in lung cancer
    Julian Downward, The Francis Crick Institute, London, England

Keynote Lecture

3:30-4:15 p.m.

  • Response and resistance to RAS inhibition in pancreatic cancer
    Andrew Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session C

4:30-6:30 p.m.

Sunday, January 31

Plenary Session 7: Resistance Mechanisms and Combinatorial Approaches for RAS Targeting

8-10 a.m.

  • Sandra Misale, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Andrew Waters, University of Cincinnati, Cincinnati, Ohio

Break

10- 10:20 a.m.

Plenary Session 8: RAS Targeting in Hematological Malignancies

10:20 a.m.- 12:20 p.m.

  •  RAS pathway activation in AML therapeutic resistance
    Catherine C. Smith, University of California, San Francisco, California
  • Mrinal Patnaik, Mayo Clinic, Rochester, Minnesota
  • Targeting RAS is aggressive multiple myeloma
    Ryan M. Young, National Cancer Institute, Bethesda, Maryland — RAS targeting in multiple myeloma

Closing Remarks

12:20 p.m.